Welcome to our dedicated page for Inhibikase Therapeutics news (Ticker: IKT), a resource for investors and traders seeking the latest updates and insights on Inhibikase Therapeutics stock.
Inhibikase Therapeutics Inc (IKT) is a clinical-stage pharmaceutical company pioneering protein kinase inhibitors for neurodegenerative disorders, including Parkinson's disease. This page serves as the definitive source for official announcements, clinical trial updates, and strategic developments from the company.
Investors and researchers will find curated updates on drug pipeline progress, regulatory milestones, and scientific advancements. Our collection includes earnings reports, partnership announcements, preclinical study results, and FDA correspondence related to candidates like Risvodetinib (IkT-148009) and IkT-001Pro.
All content is rigorously verified to ensure compliance with financial disclosure standards. Bookmark this page for real-time updates on:
• Clinical trial phases for Parkinson's-focused therapies
• Regulatory filings and agency interactions
• Peer-reviewed research publications
• Strategic collaborations in neurodegenerative research
For stakeholders tracking kinase inhibitor development and neurodegenerative treatment innovation, this resource provides essential updates directly from Inhibikase Therapeutics' corporate communications.
Inhibikase Therapeutics announced the withdrawal of its Registration Statement on Form S-1, initially filed with the SEC on April 19, 2024. The company confirmed that the S-1 had not yet been declared effective and that no securities were sold related to this filing. This action reflects a strategic decision not to proceed with the offering at this time. The press release clarifies that this announcement does not constitute an offer to sell or solicit offers to buy any securities of the company.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced outcomes from the final pre-IND meeting with the FDA for IkT-001Pro as a treatment for Pulmonary Arterial Hypertension. The FDA designated IkT-001Pro as a New Molecular Entity, allowing for exclusivity designations. The Company is preparing the IND application for Pro, a potential branded product for PAH, a deadly disease with treatment options.
FAQ
What is the current stock price of Inhibikase Therapeutics (IKT)?
What is the market cap of Inhibikase Therapeutics (IKT)?
